Amgen Declares Dividend and Receives Positive EU Opinion for Repatha Expansion

Key Facts

In a move reflecting its commitment to shareholder returns amid pharmaceutical sector pricing pressures, Amgen has declared a Q3 2026 dividend of US$2.52 per share. Alongside this financial update, the company's drug Repatha received a positive opinion from the European Medicines Agency's CHMP. This recommendation supports expanding the drug's application for cardiovascular prevention in high-risk patients, a key step in strengthening Amgen's European market presence.

The expansion of Repatha's label serves as a strategic effort to offset biosimilar competition and global drug pricing headwinds. According to reports, these regulatory milestones are critical for sustaining cash flow and revenue growth as the company navigates patent challenges. The consistent dividend payout underscores management's confidence in the ability of its diversified drug portfolio to generate sufficient liquidity for ongoing R&D and manufacturing investments.

Per market data, AMGN shares stood at US$387.64 at close on July 30, 2026, having traded between a day low of US$378.22 and a high of US$388.41. Investors are now watching how the Repatha expansion impacts long-term valuation models, particularly against the backdrop of industry-wide pricing regulations. With no major upcoming catalysts in the next seven days per the economic calendar, market attention remains on the stock's performance at these current levels.